Crystal arthropathies
Naomi Schlesinger, MD
University of Utah
Salt Lake City, Utah, United States
Disclosure(s): arthrosi: Advisor or Review Panel Member (Ongoing); horizon: Advisor or Review Panel Member (Ongoing); Novartis: Advisor or Review Panel Member (Ongoing); Olatec: Advisor or Review Panel Member (Ongoing); protalix: Advisor or Review Panel Member (Ongoing); shanton: Advisor or Review Panel Member (Ongoing); sobi: Advisor or Review Panel Member (Ongoing)
Michael Pillinger, MD
New York University Grossman School of Medicine
New York,, New York, United States
Disclosure information not submitted.
In gout, hyperuricemia promotes urate crystal deposition, which stimulates the NLRP3 inflammasome and interleukin-1β (IL-1β)-mediated arthritis. Therefore, a multifaceted approach in treatment of gouty arthritis is needed. Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition predisposing to hematologic cancers and cardiovascular disease. Given its association with IL-1β, CHIP has been investigated as a risk factor for gout. Similarly, there is growing interest in understanding the role of neutrophil extracellular traps (NETs) formation in the resolution of inflammation in gout. This session aims to capture these emerging areas in understanding the molecular mechanisms that contribute to gout pathogenesis and ones that are triggered to suppress inflammation. Dr. Pradeep Natarajan (Harvard) will talk about the emerging evidence of the role of CHIP in gout pathogenesis, Dr. Martin Herrmann (University of Erlangen-Nurnberg) will shed light on whether NET-borne elastase prevents inflammatory relapse in gout, and Dr. Khaled Elsaid (Chapman University) will provide a summary on the recent progress on the novel mechanisms that could be used to suppress inflammation in gout.
Speaker: Martin Herrmann, n/a – Friedrich-Alexander Universität Erlangen-Nürnberg
Speaker: Hang-Korng Ea, MD,PhD – Université Paris Cité, INSERM UMR 1132 BIOSCAR
Speaker: Khaled Elsaid, PhD, PharmD – Chapman University